口服抗凝治疗:在流行COVID-19时代使用和成本的最新情况
Emmanuel J Favaloro1,2,3, Leonardo Pasalic1,4, Giuseppe Lippi5
1Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW 2145, Australia.
Journal of clinical medicine
|April 26, 2025
概括
直接口服抗凝剂 (DOAC) 现在是澳大利亚最常被处方的口服抗凝剂 (OA). 尽管有趋势,但这项研究发现COVID-19对OA处方模式没有明确的影响.
科学领域:
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
- 卫生经济学 卫生经济学
背景情况:
- 口服抗凝剂治疗 (OAT) 包括维生素K抗剂 (VKA) 和直接口服抗凝剂 (DOAC).
- 了解OA使用趋势对于患者护理和资源配置至关重要.
- COVID-19大流行对OAT处方模式的影响需要调查.
研究的目的:
- 分析澳大利亚口服抗凝剂 (OA) 的使用和 1992-2024 年的成本模式.
- 具体评估COVID-19大流行期间 (2020-2024) 的趋势.
- 为了识别与不同OA类相关的处方和成本变化.
主要方法:
- 利用了澳大利亚制药福利计划 (PBS) 和医疗保险的数据.
- 分析了1992年至2024年的OA处方和成本数据,重点是2020-2024年.
- 在VKA和DOAC之间比较处方趋势.
主要成果:
- 在澳大利亚,阿皮克萨班是最常被处方的OA.
- OAT处方费用大幅增加,到2023年达到50亿美元.
- 由于DOAC仿制药和PBS定价调整,成本开始下降.
- 在OA处方趋势中没有观察到明显的COVID-19相关变化.
结论:
- 澳大利亚的OA使用数据显示,在VKA上转向DOAC.
- 尽管DOAC使用量增加,但没有发现特定的COVID-19对处方的影响.
- OAT成本很大,但由于市场动态,显示出降低的迹象.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
997
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
997
Anticoagulant Drugs: Low-Molecular-Weight Heparins
545
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
545
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388
Cardiovascular Drugs: Classification based on Therapeutic Indications
1.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
1.9K
Disorders of Hemostasis
638
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
638
Esophageal Varices-II: Clinical Features and Management
24
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
24


